Description
Latin name
Halidor
Release form
Solution for i / o administration
packaging 10 pcs
Indications of
cerebrovascular accident in cerebrovascular diseases of atherosclerotic and angiospastic origin (in combination therapy)
vascular eye diseases (incl. retinal central artery occlusion, diabetic angiopathy)
obliterating diseases of peripheral arteries of various origins, angioedema, postoperative and post-traumatic circulatory disorders
gastric and duodenal ulcer and other gastrointestinal tract, gastrointestinal tract, gastric tract, gastric tract , enteritis, colitis, tenesmus, cholecystopathy, cholelithiasis, postcholecystectomy syndrome)
urinary cramps Tay, adjuvant therapy in urolithiasis.
Contraindications
hypersensitivity to the components of the drug.
renal failure
liver dysfunction
respiratory failure
paroxysmal supraventricular or acute ventricular tachycardia
children and adolescents under 18 years of age (insufficient experience).
severe respiratory failure
severe renal failure
severe liver failure
decompensated heart failure
acute myocardial infarction.
Pregnancy and lactation
Preclinical studies have not shown any embryotoxic or teratogenic effects.
However, sufficient reliable studies on the use of the drug during pregnancy and lactation in humans have not been conducted.
Therefore, the introduction of the drug to patients in the first trimester of pregnancy is not recommended.
During lactation, you should refrain from prescribing the drug, or decide whether to stop breastfeeding during treatment.
Composition
1 amp. contains bencyclan fumarate 50 mg
Dosage and administration
Parenteral administration of the drug is administered intravenously (after dilution) or infusion.
Daily dose of 200 mg divided into 2 injections.
Side effects
Gastrointestinal: dry mouth, abdominal pain, feeling full, decreased appetite, nausea, vomiting, diarrhea.
Central nervous system: anxiety, headache, dizziness, gait disturbance, tremor, sleep disturbance, memory loss, sometimes a transient confused state of consciousness, hallucinations, asthenia, very rarely – symptoms of focal lesions of the central nervous system (CNS), epileptiform seizures.
Cardiovascular system: atrial or ventricular tachyarrhythmia can sometimes occur (especially when co-administered with other proarrhythmogenic drugs).
Laboratory parameters: transient increase in the activity of aspartate aminotransferase and alamine aminotransferase, leukopenia.
Others: general malaise, weight gain, allergic reactions.
Drug Interactions
Caution should be exercised when combined with the following agents:
anesthetics and sedatives – their effects may be enhanced by
drugs for general anesthesia – enhancement of their action by sympathomimetics reducing the level of potassium and quinidine – due to the possible summation of proarrhythmogenic effects
with digitalis drugs – increases the risk of arrhythmia in overdose of digitalis
beta-blockers – because of the opposite of chronotropic effects (negative) dosage of beta blocker
calcium channel blockers and other antihypertensive drugs – because of the possibility of enhancing their effect
drugs mi causing side effects in the form of spasmophilia – due to the possibility of summarizing these effects
acetylsalicylic acid – due to increased inhibition of platelet aggregation.
Overdose
Symptoms: increased heart rate, decreased blood pressure, collapse, incontinence, drowsiness, anxiety, and in severe cases, epileptiform seizures. A significant overdose can cause tonic-clonic seizures.
Treatment: No specific antidote is known. In case of overdosage, the stomach should be washed and symptomatic treatment prescribed. There are no data on the possible excretion of benzyclane by dialysis.
Storage conditions
The drug should be stored out of the reach of children at a temperature of 15 ° to 25 ° C.
Expiration
5 years.
Deystvuyuschee substances
Bentsyklan
pharmacy terms
prescription
Dosage form
Dosage form
solution for injection and infusion
